Tag: Pivotal

RIYADH, Saudi Arabia, July 24, 2025 /PRNewswire/ -- Raising bigger chickens for deboning and further processing has long been a challenge in Saudi Arabia's...

HONG KONG, July 23, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been...

Amsterdam, July 23, 2025

Muscle Building Supplements: A Game-Changer in Strength Training Programs

Muscle Building Supplements: A Game-Changer in Strength Training Programs

Bhatia joins Ascenda following senior roles at American Express, Chase, and Wells Fargo to grow the company's ecosystem of financial institutions and merchants into...

Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies

Investors' backing bolsters Relativity Networks' ability to meet the insatiable demand for a data transmission technology that hyperscalers require for the AI-powered economy. ORLANDO, Fla.,...

BROSSARD, QC, July 23, 2025 /CNW/ - G Mining Ventures Corp. ("GMIN" or the "Corporation") (TSX: GMIN) (OTCQX: GMINF) is pleased to announce that...

BROSSARD, QC, July 23, 2025 /PRNewswire/ - G Mining Ventures Corp. ("GMIN" or the "Corporation") (TSX: GMIN) (OTCQX: GMINF) is pleased to announce that...

Leverages AI to offer real-time support, raise service requests, and simplify complex transaction queries MUMBAI, India, July 23, 2025 /PRNewswire/ -- Axis Trustee Services Limited (ATSL),...

CEO Dr. Michael Fübi's visit reinforces India's growing role in shaping global compliance standards, sustainable industries, and future-ready workforce development. BANGALORE, India, July 23,...

ZUG, Switzerland, July 22, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), announced today the pricing of an underwritten offering of (i) 8,250,000 of its ordinary shares at a price of $20.00 per share and (ii) to one investor, pre-funded warrants to purchase 500,000 ordinary shares at a price of $19.99 per pre-funded warrant, which represents the per share public offering price for the ordinary shares less the $0.01 per share exercise price for each such pre-funded warrant. All shares and pre-funded warrants in the offering are to be sold by Pharvaris. In addition, Pharvaris has granted the underwriters a 30-day option to purchase up to an additional 1,312,500 ordinary shares at the public offering price, less underwriting discounts and commissions. The gross proceeds to Pharvaris from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $175 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about July 24, 2025, subject to satisfaction of customary closing conditions.